GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » XWELL Inc (NAS:XWEL) » Definitions » ROA %

XWELL (XWEL) ROA %

: -63.05% (As of Dec. 2023)
View and export this data going back to 2010. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. XWELL's annualized Net Income for the quarter that ended in Dec. 2023 was $-26.34 Mil. XWELL's average Total Assets over the quarter that ended in Dec. 2023 was $41.77 Mil. Therefore, XWELL's annualized ROA % for the quarter that ended in Dec. 2023 was -63.05%.

The historical rank and industry rank for XWELL's ROA % or its related term are showing as below:

XWEL' s ROA % Range Over the Past 10 Years
Min: -137.25   Med: -44.84   Max: 2.91
Current: -50.78

During the past 13 years, XWELL's highest ROA % was 2.91%. The lowest was -137.25%. And the median was -44.84%.

XWEL's ROA % is ranked worse than
81.93% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.85 vs XWEL: -50.78

XWELL ROA % Historical Data

The historical data trend for XWELL's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XWELL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -71.57 -137.25 2.91 -33.22 -50.71

XWELL Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.28 -33.13 -38.46 -78.45 -63.05

Competitive Comparison

For the Diagnostics & Research subindustry, XWELL's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XWELL ROA % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's ROA % distribution charts can be found below:

* The bar in red indicates where XWELL's ROA % falls into.



XWELL ROA % Calculation

XWELL's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-27.741/( (70.426+38.993)/ 2 )
=-27.741/54.7095
=-50.71 %

XWELL's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-26.336/( (44.55+38.993)/ 2 )
=-26.336/41.7715
=-63.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


XWELL  (NAS:XWEL) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-26.336/41.7715
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-26.336 / 29.612)*(29.612 / 41.7715)
=Net Margin %*Asset Turnover
=-88.94 %*0.7089
=-63.05 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


XWELL ROA % Related Terms

Thank you for viewing the detailed overview of XWELL's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


XWELL (XWEL) Business Description

Traded in Other Exchanges
N/A
Address
254 West 31st Street, 11th Floor, New York, NY, USA, 10001
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresCheck, XpresSpa, Treat, and HyperPointe. XpresSpa is an airport retailer of wellness services and related products. Treat is a travel health and wellness brand that offers in-airport spa and wellness medical services. XpresCheck provides Covid-19 screening and diagnostic testing in partnership with the CDC. HyperPointe is a digital healthcare and data analytics relationship company.
Executives
Suzanne A. Scrabis officer: Chief Financial Officer C/O XWELL, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Scott R Milford officer: Chief Executive Officer C/O TOWN SPORTS INTERNATIONAL, LLC, 5 PENN PLAZA, NEW YORK NY 10001
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Ezra Ernst officer: See Remarks C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Omar Haynes officer: VP Treas & Fi & Interim CFO C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Doug Satzman director, officer: Chief Executive Officer 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
James A. Berry officer: Chief Financial Officer C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Michael Lebowitz director 780 THIRD AVENUE, 12TH FLOOR, C/O XPRESSPA GROUP, INC., NEW YORK NY 10017
Donald E. Stout director 780 THIRD AVENUE, 15TH FLOOR, NEW YORK NY 10017
Mistral Spa Holdings, Llc 10 percent owner C/O MISTRAL CAPITAL MANAGEMENT, LLC, 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Mistral Capital Management, Llc 10 percent owner 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Andrew R Heyer other: Former director and 10% owner 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Calm.com, Inc. 10 percent owner 140 2ND STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Edward Jankowski officer: SVP; CEO of XpresSpa C/O FORM HOLDINGS CORP., 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017